IL-2 Low dose

Phase 2Small molecule

UUniversity Hospital, Limoges

IL-2 Low dose is one of 12 small molecule programs targeting Idiopathic Nephrotic Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic Nephrotic SyndromeActive, not recruiting

Idiopathic Nephrotic SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Idiopathic Nephrotic Syndrome

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Approved

5 2

Rituxan

Roche

Phase 3

7 3

Gazyva

Roche

Phase 3

1 4

Medrol

Pfizer

Phase 3

1 5

Depakote

AbbVie

Phase 3

1 6

Tylenol

KKenvue Brands

Phase 3

1 7

Diphenhydramine Hcl

Roche

Phase 3

1 8

Kesimpta

Novartis

Phase 2

2 9

Singulair

OOrganon and Co

Preclinical

1 10

Fresh Frozen Plasma

CSL Behring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Idiopathic Nephrotic Syndrome1 trial

Treatment of Steroid Dependent Idiopathic Nephrotic Syndrome in Children With Low Doses of Interleukin 2: a Pilot Study

Withdrawn·UUniversity Hospital, Limoges·Phase 2·NCT02997150

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IL-2 Low dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IL-2 Low dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IL-2 Low dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Limoges company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity Hospital, Limoges

IL-2 Low dose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Idiopathic Nephrotic Syndrome1 trial

References

Drug Info

Quick Facts

Related News